6,310 Shares in Masimo Corporation $MASI Bought by Navellier & Associates Inc.

Navellier & Associates Inc. acquired a new stake in shares of Masimo Corporation (NASDAQ:MASI) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 6,310 shares of the medical equipment provider’s stock, valued at approximately $931,000.

Several other hedge funds and other institutional investors have also made changes to their positions in MASI. MAI Capital Management boosted its stake in shares of Masimo by 176.7% during the 2nd quarter. MAI Capital Management now owns 202 shares of the medical equipment provider’s stock worth $34,000 after purchasing an additional 129 shares during the period. Smartleaf Asset Management LLC lifted its stake in Masimo by 80.0% in the third quarter. Smartleaf Asset Management LLC now owns 306 shares of the medical equipment provider’s stock worth $44,000 after purchasing an additional 136 shares during the last quarter. Allworth Financial LP lifted its stake in Masimo by 72.8% in the second quarter. Allworth Financial LP now owns 387 shares of the medical equipment provider’s stock worth $65,000 after purchasing an additional 163 shares during the last quarter. Hantz Financial Services Inc. boosted its position in shares of Masimo by 792.3% during the third quarter. Hantz Financial Services Inc. now owns 580 shares of the medical equipment provider’s stock valued at $86,000 after buying an additional 515 shares during the period. Finally, Quantbot Technologies LP bought a new position in shares of Masimo during the second quarter valued at approximately $86,000. Hedge funds and other institutional investors own 85.96% of the company’s stock.

Masimo Trading Down 0.5%

Shares of NASDAQ MASI opened at $134.10 on Wednesday. Masimo Corporation has a twelve month low of $125.94 and a twelve month high of $194.88. The firm has a market cap of $7.20 billion, a PE ratio of -12.72, a price-to-earnings-growth ratio of 1.37 and a beta of 1.26. The business has a fifty day simple moving average of $136.97 and a two-hundred day simple moving average of $143.18. The company has a quick ratio of 1.92, a current ratio of 2.84 and a debt-to-equity ratio of 0.69.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Wall Street Zen upgraded Masimo from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. Bank of America initiated coverage on Masimo in a research report on Monday, November 17th. They issued a “neutral” rating and a $162.00 price objective on the stock. Zacks Research downgraded Masimo from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 24th. Wells Fargo & Company reissued an “overweight” rating and set a $190.00 target price on shares of Masimo in a research note on Friday, December 5th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a research note on Monday, December 1st. Four research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $189.40.

About Masimo

Masimo (NASDAQ: MASI) is a global medical technology company specializing in noninvasive monitoring solutions. The company’s flagship technology, Masimo SET® (Signal Extraction Technology), enhances the accuracy of pulse oximetry in challenging clinical conditions. Beyond pulse oximetry, Masimo’s portfolio extends to brain function monitoring, regional oximetry, and acoustic respiration rate monitoring, serving critical, acute, and ambulatory care settings.

In addition to its core monitoring technologies, Masimo offers a range of patient cables, sensors, and connectivity platforms designed to integrate with hospital information systems and remote monitoring applications.